Stalter Randy M, Katayamoyo Patrick, Packer Catherine, Banda Harry, Chen Pai-Lien, Mwansa Jonathan K, McCarraher Donna R, Denison Julie A
From the *Global Health, Population and Nutrition Group, FHI 360, Durham, North Carolina; †Clinical Care Unit, FHI 360, Lusaka, Zambia; ‡FHI 360, Ndola, Zambia; §Arthur Davison Children's Hospital, Ndola, Zambia; and ¶Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Pediatr Infect Dis J. 2017 Aug;36(8):768-773. doi: 10.1097/INF.0000000000001547.
Adolescents living with HIV (ALHIV) experience less favorable antiretroviral therapy (ART) outcomes than other age groups. First-line treatment failure complicates ART management as second-line regimens can be costlier and have greater pill burdens. Understanding predictors of switching ART regimens and adherence among adolescents on second-line ART may help to prevent poor treatment outcomes.
A quantitative survey was administered to 309 ALHIV attending 3 ART clinics in the Copperbelt Province, Zambia. Medical chart data, including pharmacy refill data, were abstracted. Associations between being on second-line ART and sociodemographic, psychosocial and ART adherence characteristics were tested. Cox proportional hazards models were used to estimate the effect of baseline ART variables on time to switching.
Ten percent of participants were on second-line regimens. Compared with ALHIV on first-line ART, adolescents on second-line regimens were older (P = 0.02), out of school due to completion of secondary studies (P = 0.04) and on ART longer (P = 0.03). Adolescents on second-line regimens were more likely to report missing ≥48 consecutive hours of drugs in the last 3 months (P = 0.01). Multivariable analysis showed that adolescents who initiated ART with efavirenz-based regimens were more likely to switch to second-line than those put on nevirapine-based regimens (hazard ratio = 2.6; 95% confidence interval: 1.1-6.4).
Greater support is needed for ALHIV who are on second-line regimens. Interventions for older adolescents that bridge the gap between school years and young adulthood would be helpful. More research is needed on why ALHIV who start on efavirenz-based regimens are more likely to switch within this population.
感染艾滋病毒的青少年(ALHIV)与其他年龄组相比,抗逆转录病毒疗法(ART)的效果较差。一线治疗失败使ART管理变得复杂,因为二线治疗方案成本更高且服药负担更大。了解二线ART治疗的青少年更换ART方案和坚持治疗的预测因素可能有助于预防不良治疗结果。
对赞比亚铜带省3家ART诊所的309名ALHIV进行了定量调查。提取了包括药房配药数据在内的病历数据。测试了接受二线ART治疗与社会人口学、心理社会和ART依从性特征之间的关联。使用Cox比例风险模型估计基线ART变量对换药时间的影响。
10%的参与者接受二线治疗方案。与接受一线ART治疗的ALHIV相比,接受二线治疗方案的青少年年龄更大(P = 0.02),因完成中学学业而辍学(P = 0.04),接受ART治疗的时间更长(P = 0.03)。接受二线治疗方案的青少年更有可能报告在过去3个月内连续漏服药物≥48小时(P = 0.01)。多变量分析显示,以依非韦伦为基础方案开始ART治疗的青少年比接受奈韦拉平为基础方案的青少年更有可能更换为二线治疗(风险比 = 2.6;95%置信区间:1.1 - 6.4)。
需要为接受二线治疗方案的ALHIV提供更多支持。针对年龄较大青少年的干预措施,弥合学年与青年期之间的差距会有所帮助。对于为何以依非韦伦为基础方案开始治疗的ALHIV在该人群中更有可能更换治疗方案,还需要更多研究。